The Cardiorenal Syndrome in Heart Failure Van N Selby, MD - - PDF document

▶
the cardiorenal syndrome in heart failure
SMART_READER_LITE
LIVE PREVIEW

The Cardiorenal Syndrome in Heart Failure Van N Selby, MD - - PDF document

Sep 09, 2022 138 likes •346 views

10/10/2015 The Cardiorenal Syndrome in Heart Failure Van N Selby, MD Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015 Disclosures None 1 10/10/2015 Cardiorenal Syndrome (CRS) A pathophysiologic disorder

slide-1
SLIDE 1

10/10/2015 1

The Cardiorenal Syndrome in Heart Failure

Van N Selby, MD

Assistant Professor of Medicine Advanced Heart Failure Program, UCSF October 9, 2015

Disclosures

None

slide-2
SLIDE 2

10/10/2015 2

Cardiorenal Syndrome (CRS)

A pathophysiologic disorder of the heart and kidneys whereby acute or chronic dysfunction in one organ may induce acute or chronic dysfunction in the other organ

Ronco C et al. J Am Coll Cardiol. 2008; 52: 1527-1539.

Heart-kidney Interactions

  • A bidirectional relationship
  • The heart is directly dependent on regulation of salt and

water by the kidneys

  • The kidneys are dependent on blood flow and pressure

generated by the heart

  • The effects can be both acute and chronic
  • Mortality is increased in HF patients with a reduced

glomerular filtration rate (GFR)

  • Acute or chronic systemic disorders can cause both

cardiac and renal dysfunction

slide-3
SLIDE 3

10/10/2015 3

Types of CRS

Ronco C et al. J Am Coll Cardiol. 2008; 52: 1527-1539.

Type I (Acute Cardiorenal Syndrome) Abrupt worsening of cardiac function (e.g. ADHF) leading to acute kidney injury. Type II (Chronic Cardiorenal Syndrome) Chronic HF causing progressive CKD Type III (Acute Renocardiac Syndrome) Abrupt worsening of renal function (e.g. acute kidney ischemia or glomerulonephritis) causing acute cardiac dysfunction (e.g. HF) Type IV (Chronic Renocardiac Syndrome) Chronic kidney disease (e.g. chronic glomerular disease) contributing to cardiac dysfunction and/or increased risk of adverse cardiovascular events. Type V (Secondary Cardiorenal Syndrome) Systemic disorders (e.g. diabetes mellitus, sepsis) causing both cardiac and renal dysfunction.

Epidemiology of CRS

  • 30-60% of HF patients have CKD (eGFR < 60 mL/min/1.73 m2)
  • ADHERE: Only 9% of patients had normal GFRCRS often complicates the

management of HF:

  • 20-30% of patients had a rise in serum creatinine > 0.3 mg/dL
  • Risk factors include DM, admission creatinine > 1.5 mg/dL, uncontrolled

hypertension

  • Renal dysfunction is associated with 2-fold increase in mortality
  • Type I CRS:
  • The rise in serum creatinine usually occurs within 5 days of admission
  • ADHF, post-MI, post-cardiac surgery
  • Associated with increased LOS, readmissions, and post-discharge mortality

Smith GL et al, JACC 2006 Heywood JT J Card Fail 2007

slide-4
SLIDE 4

10/10/2015 4

Diagnosis of CRS

  • Usually based on the serum creatinine
  • Caution in older, sicker patients
  • Most eGFR equations assume the serum creatinine concentration is stable
  • In those with HF and reduced GFR, one must distinguish underlying

kidney disease from impaired function related to CRS

  • Proteinuria
  • Active sediment
  • Small kidneys on imaging
  • None of these can rule out intrinsic kidney disease
  • BUN/Cr often used, but should not be used to decide regarding diuretics
  • Urine sodium concentration < 25 is more consistent with HF

Pathophysiology of CRS

Hemodynamic

 systemic perfusion  renal blood flow (RBF)

Impaired intra-renal autoregulation

 central venous pressure (CVP) and intraabdominal

pressure   renal venous pressure (RVP) Non-hemodynamic

 SNS, RAAS, AVP activation -> impaired intra-renal

autoregulation

 systemic inflammation  cytokine release and

intra-renal vasculature endothelial dysfunction

slide-5
SLIDE 5

10/10/2015 5

GFR Regulation in HF

Cody RJ et al. Kidney International. 1988; 34: 361-367.

34 pts with HF, off meds, multiple hemodynamic and neurohormonal parameters assessed What accounts for variability in GFR: RBF 69%, FF 25%

Organ-specific factors in CRS

Damman K et al. Eur Heart J. 2014; 35: 3413-3416.

slide-6
SLIDE 6

10/10/2015 6

Hemodynamics and CRS Type I

Mullens W et al. J Am Coll Cardiol. 2009; 53: 589-596.

CVP was a better predictor of low GFR on discharge than CO

CRS: Glomerular factors

Damman K et al. Eur Heart J. 2014; 35: 3413-3416.

slide-7
SLIDE 7

10/10/2015 7

Nephron-specific factors in CRS

Damman K et al. Eur Heart J. 2014; 35: 3413-3416.

Hemodynamic Profile in CRS Type I

Haase M et al. Contrib Nephrol. 2013; 182: 99-116.

Congestion at Rest Low Perfusion at Rest

  • Discordantly  RBF
  • Intra-renal microvascular

dysregulation

Warm & Dry Warm & Wet Cold & Wet NO NO YES YES Cold & Dry

  • Discordantly  RBF
  • Impaired intra-renal

autoregulation

  • Renal v. pressure 
  •  RBF
  • Impaired intra-renal

autoregulation

  •  RBF
  • Impaired intra-renal

autoregulation

  • Renal v. pressure 
slide-8
SLIDE 8

10/10/2015 8

Non-hemodynamic factors in CRS

  • Modulation of RAAS
  • Angiotensin II promotes renal fibrosis, causes SNS activation
  • Inflammation/oxidative stress
  • Endothelial dysfunction
  • Humoral/cellular immunity
  • Anemia

Management of CRS

No therapy has been clearly shown to improve

  • utcomes in CRS

Careful management of

Fluid status CVP Cardiac Output SVR/ BP (renal perfusion) Pre existing renal disease (urine protein)

Avoid mismatches between these factors

slide-9
SLIDE 9

10/10/2015 9

Management of CRS

Managing volume

Diuretics Aquaretics (i.e. vasopressin antagonists) Dopamine Inotropes Ultrafiltration

Preventing decreases in RBF and FF:

Keeping plasma refill rate (PRF) constant Preventing excessive intra-renal vasodilatation/ vasoconstriction

Diuretic Strategies in CRS

Jentzer JC et al. J Am Coll Cardiol. 2010; 56: 1527-1534.

slide-10
SLIDE 10

10/10/2015 10

Diuretic Resistance

Brater DC. N Engl J Med. 1998; 339: 387-395.

“Braking” phenomenon

  • Decrease in response to diuretic after

the first dose given

Long-term tolerance

  • Tubular hypertrophy to compensate

for salt loss

Post-diuretic NaCl retention Diuretic malabsorption

  • GI edema

Reduced GFR Aldosterone antagonism

Diuretics increase neurohormonal activation

Plasma Renin Activity (ng/mL/h) Before Diuretic (n = 12) After Diuretic (n = 11) 50 10 2.5 0.5 Plasma Aldosterone (pmol/L) Before Diuretic (n = 12) After Diuretic (n = 11) 1000 600 200 100 Mean (95% CI) Mean (95% CI)

Bayliss J, et al. Br Heart J 1987

slide-11
SLIDE 11

10/10/2015 11

Survival and Diuretic Dose in HF

Eshaghian S et al. Am J Cardiol. 2006; 97: 1759-1764.

Dosing Diuretics: DOSE HF Trial

Felker GM et al. N Engl J Med. 2011; 364: 797-805.

slide-12
SLIDE 12

10/10/2015 12

Dosing Diuretics: DOSE HF Trial

Felker GM et al. N Engl J Med. 2011; 364: 797-805.

Low High p value

Dyspnea VAS AUC at 72 hrs 4478 4668 0.041 % free from congestion at 72 hrs 11% 18% 0.091 Change in weight at 72 hrs

  • 5.3 lbs
  • 8.2 lbs

0.011 Net volume loss at 72 hrs 3575 mL 4899 mL <0.001 % Treatment failure 37% 40% 0.56 % with Cr > 0.3 mg/dL at 72 hrs 14% 23% 0.041 Length of stay, days (median) 6 5 0.55

  • High dose better efficacy, more worsening Cr
  • No difference bolus vs. drip

Tolvaptan

  • Inappropriate elevation of arginine vasopressin plays a key role in

mediating water retention

  • Tolvaptan is a small molecule antagonist of the V2 receptor
  • Compared to furosemide:
  • Similar effect on urine output
  • No effect on electrolytes or osmolality
  • Preserves renal blood flow
  • Improves hemodynamics (RAP, PCWP, CI, SVR)
  • The EVEREST trial randomized 4133 patients hospitalized for heart failure

to tolvaptan vs placebo in addition to standard therapy for HF

  • Overall, a negative trial (no effect on the primary endpoint)

Udelson JE et al. J Am Coll Cardiol. 2008

slide-13
SLIDE 13

10/10/2015 13

Dyspnea in Hospitalized Patients with Hyponatremia

Hauptman PJ et al. J Card Fail. 2013; 19: 390-397.

Tolvaptan in hospitalized patients with hyponatremia

Hauptman PJ et al. J Card Fail. 2013; 19: 390-397.

slide-14
SLIDE 14

10/10/2015 14

Managing Volume Overload in Heart Failure: Diuretics vs. Vaptans

Vaptans Diuretics

Urine Output   Serum Sodium   Serum Potassium No change  Plasma Osmolality   Blood Pressure No change  BUN/Creatinine No change  Renal Blood Flow   GFR   Renal vascular resistance   Vasopressin level   Norepinephrine level No change  Plasma renin activity No change  Aldosterone level No change 

Dopamine Effects in HF

Elkayam U. Circulation. 2008; 117: 200-205.

  • Small series found that dopamine can significantly increase GFR in

patients with moderate or severe HF

  • Increases RBF at doses of 2-10 mcg/kg/min
  • Due to dilation of both large and small resistance renal blood vessels
  • Also increases cardiac output, but the improvement in RBF was

disproportionately higher

slide-15
SLIDE 15

10/10/2015 15

Dopamine Effects in HF: DAD HF

Giamouzis G et al. J Card Fail. 2010;16:922-930.

Dopamine Effects in HF: DAD HF

Giamouzis G et al. J Card Fail. 2010;16:922-930.

slide-16
SLIDE 16

10/10/2015 16

Dopamine Effects in HF: ROSE AHF

Chen HH et al. JAMA. 2013; 310: 2533-2543.

Ultrafiltration for ADHF: UNLOAD

  • Mechanical strategy for fluid removal
  • The UNLOAD trial randomized 20 patients hospitalized for ADHF to usual

care vs up front ultrafiltration

  • UF rate/duration at the discretion of the institution
  • Early UF was associated with greater weight reduction compared to IV

diuretics, without significant difference in serum creatinine

  • No impact on dyspnea
  • Early UF reduced:
  • 90-day rehospitalizations
  • ED and unscheduled office visits
  • Days of rehospitalization for HF

Costanzo MR et al, JACC 2007

slide-17
SLIDE 17

10/10/2015 17

Ultrafiltration for ADHF: CARRESS

  • Examined the efficacy of ultrafiltration in ADHF complicated by worsening

renal function

  • Randomized 188 patients with ADHF, worsened renal function, and
  • ngoing congestion to stepped pharmacologic therapy vs ultrafiltration
  • The primary outcome was the bivariate change from baseline in serum

creatinine and body weight at 96 hours

Ultrafiltration in Acute HF: CARESS

Bart BA. et al. N Engl J Med. 2012

slide-18
SLIDE 18

10/10/2015 18

AVOID-HF

  • Aim: to determine whether UF prolonged the time to first HF event within

90 days of discharge

  • When fluid removal therapy is adjusted in both arms
  • Patients hospitalized for a primary diagnosis of HF were randomized

within 24 hours to adjustable UF or adjustable loop diuretics

  • Guidelines for UF and diuretics were based on renal function and vital

signs

  • The study was terminated early unilaterally by the sponsor after enrollment
  • f 224 patients (27.5%) due to slow enrollment

Costanzo MR et al, JACC HF in press

AVOID-HF: Time to HF event after discharge

Costanzo MR et al, JACC HF in press

slide-19
SLIDE 19

10/10/2015 19

Plasma Refill Rate

Boyle A. J Card Fail. 2006; 12: 247-249.

  • PRR = ECV – U output
  • Monitor with the serum Hct
  • Keep Hb/ Htc from rising > 3-5% in 8-12 hrs

Conclusions

  • CRS is common and is associated with worse
  • utcomes
  • Reduced renal perfusion and venous congestion are

prominent factors

  • Management requires careful balance between

volume status, renal perfusion, and intra-renal hemodynamics

  • Thoughtful approach to volume management
  • Diuretics: loop (bumetanide) +/- thiazide Consider

tolvaptan

  • Use ultrafiltration if massive or refractory volume overload